Navigation Links
Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
Date:2/3/2009

FREISING-WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin(R) candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability.

Having successfully demonstrated the mode of action of PRS-050 in vitro and in vivo, Pieris has now validated the efficacy of the Anticalin(R) product candidate in several preclinical models. Amongst those tested, DCE-MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging) has been established and validated to monitor immediate treatment effects in the upcoming Phase I clinical trial. Production process parameters for GMP manufacture of PRS-050 have also been clearly defined. Initial toxicology results have shown that PRS-050 is very well tolerated.

Progress in the PRS-050 program demonstrates that Pieris has fulfilled critical speed and capacity goals in producing Anticalins(R) as clinical product candidates. Discovery programs can be advanced from lead candidate to GMP production in less than twelve months. Furthermore, several grams per liter production of Anticalins(R) in Wacker Biotech's proprietary bacterial secretion system ESETEC(R) supports broad therapeutic application of the Anticalin(R) technology.

In light of the progress in its lead proprietary program, the Company also announced the expansion of its Management Team with the appointment of Dr Kristian Jensen as Chief Operating Officer. Dr Angelika Stern will henceforth be fully dedicated to management of the PRS-050 program in her new function as Head of Project Management Angiogenesis.

Kristian Jensen joins Pieris from Merck Serono, where he spent almost three years establishing and managing its phage display antibody facility in Geneva, Switzerland. Prior to Merck
'/>"/>

SOURCE Pieris AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
2. MannKind Reports Successful Completion of Device Bioequivalence Trial
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
5. Pharmasset Reports Fiscal Year End 2008 Financial Results
6. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
7. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
8. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
9. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
10. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
11. GEN Reports on the Trend Toward Predictive Toxicogenomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Md. , Oct. 24, 2014  The ... highlighted the latest results achieved by ... system. The National Precursor Log ... at the point of sale and helps flag ... narcotics agents often set up NPLEx "watch lists" ...
(Date:10/25/2014)... 2014 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Monday, November 3, 2014 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has ... mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, ... mg, 10 mg/40 mg and 10 mg/80 mg, the generic version ... treatment of hypertension. Caduet Tablets had U.S. sales ...
... Inc. reported today that it has completed enrollment in ... product expressing the neurturin (NRTN) gene for the treatment ... patients at 11 medical centers throughout the United States.  ... provide constant, sustained expression of neurturin (NRTN), a neurotrophic ...
Cached Medicine Technology:Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 2Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 3Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 4
(Date:10/26/2014)... 2014 The “LoveHandle" was featured on ... Report, which features the latest and coolest technology products ... expert and technology reporter for NewsWatch, conducted the product ... phones off the ground. , According to eMarketer, US ... operating a mobile device, and that doesn’t include talking. ...
(Date:10/26/2014)... 26, 2014 Revenue Masters Cloud Contract ... user-friendly software recently launched. Cloud Contract Modeling™ ... rates, including bundled payments and government reimbursement. Instead of ... be automatically checked against the payer contract to ensure ... , Revenue Masters, LLC, is a healthcare revenue cycle ...
(Date:10/25/2014)... Triton Algae Innovations, ... Dr. Xun Wang has joined the firm as ... Triton has developed a patented synthetic biology platform for ... Dr. Wang, the platform uses algae to produce novel ... “Algae are unique because they can produce compounds that ...
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... Wisconsin (PRWEB) October 25, 2014 QueenBeeTickets.com ... for a great selection at affordable prices. Bob Seger ... Center Huntington Center and Nationwide Arena are going on ... , Click Here to browse the selection ... Band at QueenBeeTickets.com. , The famous singer is touring ...
Breaking Medicine News(10 mins):Health News:A New Method for Keeping Mobile Devices from Falling was Featured on NewsWatch Television on October 16, 2014 2Health News:Keeping Hospitals Doors Open with Affordable Software Now Available 2Health News:Keeping Hospitals Doors Open with Affordable Software Now Available 3Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... massive egg recall due to salmonella contamination has probably made you ... But now some time has passed, and you,re starting to ... the eggs languishing in your fridge or are you inviting a ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If ... overindulgence can be easily worked off at the gym, think ... month,s worth of unhealthy living changes physiology, making piled-on fat ... can have later long-term effects," said study co-author Dr. Torbjorn ...
... physical and emotional problems a year after surgery than before ... the key findings of a research study of more than ... Surgery . Researchers from The Netherlands spoke to ... 54, who had undergone planned surgery, ranging from plastic surgery ...
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay News) -- A ... death after taking the glucose-lowering diabetes drugs Avandia and Actos ... to numerous other studies that found that the risk was ... findings are, however, in line with some other previous studies, ...
... times could be cut by over one third and patients, ... approach to the triage process of sorting patients for ... International Journal of Six Sigma and Competitive Advantage ... Zarqa, Jordan and colleagues have turned to a design strategy ...
... Reporter , TUESDAY, Aug. 24 (HealthDay News) -- Pregnant ... should not worry that their use will cause birth ... of women develop herpes simplex during the first trimester ... antiviral drugs such as acyclovir (Zovirax), valacyclovir (Valtrex) and ...
Cached Medicine News:Health News:Are The Eggs in Your Fridge Safe to Eat? 2Health News:Are The Eggs in Your Fridge Safe to Eat? 3Health News:Are The Eggs in Your Fridge Safe to Eat? 4Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 3Health News:Engineering shorter wait times in the ER 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: